Evidence map›Paper›PMID 30187640›Full record

ArticleJournal of viral hepatitis2019

Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort.

Mary A Rodgers, Vera Holzmayer, Ana Vallari, Ana Olivo, Kenn Forberg, Jill Fuhrman, Kelly E Coller, Bih Awazi, Jules Bertrand Kenmegne Sidje, Matthew B Frankel and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of viral hepatitis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Characterization of near-complete humanMicrobiology resource announcements · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Mary A RodgersAbbott Laboratories, Abbott Park, Illinois, USA.ORCID 0000-0001-8815-8651
Vera HolzmayerAbbott Laboratories, Abbott Park, Illinois, USA.
Ana VallariAbbott Laboratories, Abbott Park, Illinois, USA.
Ana OlivoAbbott Laboratories, Abbott Park, Illinois, USA.
Kenn ForbergAbbott Laboratories, Abbott Park, Illinois, USA.
Jill FuhrmanAbbott Laboratories, Abbott Park, Illinois, USA.
Kelly E CollerAbbott Laboratories, Abbott Park, Illinois, USA.
Bih AwaziUniversité de Yaoundé I, Yaoundé, Cameroon.
Jules Bertrand Kenmegne SidjeUniversité de Yaoundé I, Yaoundé, Cameroon.
Matthew B FrankelAbbott Laboratories, Abbott Park, Illinois, USA.
Michael G BergAbbott Laboratories, Abbott Park, Illinois, USA.
Dora MbanyaUniversité de Yaoundé I, Yaoundé, Cameroon.
Nicaise NdembiInstitute of Human Virology, Abuja, Nigeria.
Gavin A ClohertyAbbott Laboratories, Abbott Park, Illinois, USA.
Abbott Fund · USUniversité de Yaoundé I · CMInstitute of Human Virology · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of chronic hepatitis C virus (HCV) and the presence of human pegivirus 2 (HPgV-2) have not been examined in Cameroon, although HCV has been associated with HPgV-2 infections previously. Herein we aimed to characterize the burden and genetic diversity of HCV and the presence of HPgV-2 in Cameroon. Retrospective plasma specimens collected from N = 12 369 consenting subjects in South Cameroon from 2013 to 2016 were included in the study. The majority (97.1%) of participants were patients seeking health care. All specimens were screened for HCV using the Abbott RealTime HCV viral load assay and positive specimens with remaining volume were also screened for HPgV-2 antibodies on the Abbott ARCHITECT instrument, followed by molecular characterization. Overall, HCV RNA was detected in 305 (2.47%; 95% CI: 2.21%-2.75%) specimens. Notably, the prevalence of HCV RNA was 9.09% amongst participants over age 40 and 3.81% amongst males. Phylogenetic classification of N = 103 HCV sequences identified genotypes 1 (19.4%), 2 (15.5%) and 4 (65.1%) within the study cohort. Amongst HCV RNA-positive specimens, N = 28 (10.6%; 95% CI: 7.44%-14.90%) specimens also had detectable HPgV-2 antibodies. Of these, N = 2 viremic HPgV-2 infections were confirmed by sequencing and shared 93-94 median % identity with strains found on other continents. This is the first study to determine the prevalence of chronic HCV in Cameroon, and the discovery of HPgV-2 in this study cohort expands the geography of HPgV-2 to the African continent, indicating a widespread distribution exists.

Indexed as

Epidemiological MonitoringAdolescentAdultAgedAged, 80 and overAntibodies, ViralCameroonChildChild, PreschoolCoinfectionFemaleFlaviviridaeFlaviviridae InfectionsHepacivirusHepatitis C, ChronicHumansAntibodies, ViralRNA, ViralCameroonchronic HCVhuman pegivirus 2 (HPgV-2)surveillanceviral diversity

Identifiers

PMID30187640
PMCPMC7379692
OpenAlexW2891637410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.